Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy

AIDS

Volumn 22, Issue 12, 2008, Pages 1417-1423

  Peuchant, Olivia ^a   Thiébaut, Rodolphe ^b   Capdepont, Sophie ^a   Lavignolle Aurillac, Valérie ^b   Neau, Didier ^a,b   Morlat, Philippe ^a   Dabis, François ^b   Fleury, Hervé ^a   Masquelier, Bernard ^a,c  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c HÔPITAL PELLEGRIN   (France)

Author keywords

Antiretroviral therapy; HIV 1 drug resistance; Minority variants; Transmission

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1; VIRUS RNA;

ADULT; ALLELE; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNITY; MAJOR CLINICAL STUDY; MALE; PLASMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEROCONVERSION; TREATMENT RESPONSE; VALIDATION STUDY; VIRUS DETECTION; VIRUS LOAD; VIRUS RESISTANCE; VIRUS TRANSMISSION; ANTIVIRAL RESISTANCE; BLOOD; DISEASE TRANSMISSION; DRUG EFFECT; GENETICS; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; METHODOLOGY; MUTATION; RETROSPECTIVE STUDY; VIROLOGY;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MUTATION; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; RNA, VIRAL; VIRAL LOAD;

EID: 49849095346     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283034953     Document Type: Article

References (22)

1. Costagliola D, Descamps D, Assoumou L, Morand-Joubert L, Marcel in AG, Brodard V, et al. Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study. J Acquir Immune Defic Syndr 2007; 46:12-18.
2. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro MF, Bozzette SA, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004; 18:1393-1401.
3. Masquelier B, Bhaskaran K, Pillay D, Gifford R, Balestre E, Jørgensen LB, et al. Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr 2005; 40:505-511.
4. Wensing AM, van de Vijver DA, Angarano G, Asjö B, Balotta C, Boeri E, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192:958-966.
5. Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, DouglasJMJr, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004; 189:2174-2180.
6. Brenner BG, Roger M, Routy J P, Moisi D, Ntemgwa M, Matte C, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007; 195:951-959.
7. Chaix ML, Desquilbet L, Cottalorda J, Descamps D, Deveau C, Galimand J, et al. Sub-optimal response to HAART in patients treated at time of primary HIV-1 infection and infected with HIV resistant strains. Antivir Ther 2005; 10:S127.
8. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-394.
9. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288:181-188.
10. Pillay D, Bhaskaran K, JurriaansS, PrinsM, Masquelier B, Dabis F, et al. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS 2006; 20:21-28.
11. Metzner KJ, Rauch P, Walter H, Boesecke C, Zöllner B, Jessen H, et al. Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS 2005; 19:1819-1825.
12. Lazaro E, Coureau G, Guedj J, Blanco P, Pellegrin I, Com-menges D, et al. Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection. Antivir Ther 2006; 11:343-350.
13. Yeni P. Guidelines for therapeutic management of HIV-infected patients. Paris: Médecine-Sciences Flammarion; 2006.
14. Metzner KJ, Bonhoeffer S, Fischer M, Karanicolas R, Allers K, Joos B, et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis 2003; 188:1433-1443.
15. Thiébaut R, Jacmin-Gadda H. Mixed models for longitudinal left-censored repeated measures. Comput Methods Program Biomed 2004; 74:255-260.
16. Johnson J, Li J-F, Wei X, Lipscomb J, Smith A, Heneine W. Sensitive testing demonstrates a high prevalence of transmitted drug resistance among conventionally genotyped wildtype HIV-1 infections. Antivir Ther 2007; 12:S46.
17. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267:483-489.
18. Wainberg MA. The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev Anti Infect Ther 2004; 2:147-151.
19. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003; 37:113-128.
20. Castagna A, Danise A, Menzo S, Galli L, Gianotti N, Carini E, et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS 2006; 20:795-803.
21. Metzner KJ, Rauch P, Von Wyl V, Kuster H, Stellbrink HJ, Boni J, et al. Prevalence of minority quasispecies of drug-resistant HIV-1 in patients with primary HIV-1 infection in Zurich in the years 2002-2006. Antivir Ther 2007; 12:S47.
22. Johnson J, Li J-F, Wei X, Lipscomb J, Smith A, Stone C, et al. Low-frequency mutations substantially increase the prevalence of transmitted drug resistance and greatly strengthen the relationship between resistance mutations and virological failure. Proceeding of the 14th Conference on Retroviruses and Opportunistic Infections [abstract 639]; 25-28 February; Los Angeles, CA, USA.